US regulatory status: approved.
pharma · NASH With Fibrosis · NASH - Nonalcoholic Steatohepatitis · HEPA
Hepion Pharmaceuticals
Hepion Pharmaceuticals drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Morristown, USA HQ
4 Employees
Public company Type
HEPA · NYSE Ticker
Company details
- Status
- Public
- HQ
- Morristown, USA
- Employees
- 4
- Programs
- 5
- Drugs
- 2
- Patents
- 1
Hepion Pharmaceuticals pipeline
Portfolio lens on 2 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Hepion Pharmaceuticals drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
diphtheria (d), tetanus (t), pertussis (acellular, component) (pa), hepatitis b (rdna) (hbv), poliomyelitis (inactivated) (ipv) and haemophilus influenzae type-b (hib) conjugate vaccine (adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Hepion Pharmaceuticals's portfolio.